Neurexin 2 p.G849D variant, implicated in Parkinson's disease, increases reactive oxygen species, and reduces cell viability and mitochondrial membrane potential in SH-SY5Y cells.
Cell viability
Mitochondrial membrane potential
Neurexin 2α (NRXN2)
Oxidative stress
Parkinson’s disease
p.G849D variant
Journal
Journal of neural transmission (Vienna, Austria : 1996)
ISSN: 1435-1463
Titre abrégé: J Neural Transm (Vienna)
Pays: Austria
ID NLM: 9702341
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
17
05
2022
accepted:
10
10
2022
pubmed:
16
10
2022
medline:
15
11
2022
entrez:
15
10
2022
Statut:
ppublish
Résumé
Parkinson's disease (PD) is a neurodegenerative movement disorder, affecting 1-2% of the human population over 65. A previous study by our group identified a p.G849D variant in neurexin 2α (NRXN2) co-segregating with PD, prompting validation of its role using experimental methods. This novel variant had been found in a South African family with autosomal dominant PD. NRXN2α is an essential synaptic maintenance protein with multiple functional roles at the synaptic cleft. The aim of the present study was to investigate the potential role of the translated protein NRXN2α and the observed mutant in PD by performing functional studies in an in vitro model. Wild-type and mutant NRXN2α plasmids were transfected into SH-SY5Y cells to assess the effect of the mutant on cell viability and apoptosis [(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) Assay; ApoTox-Glo™ Triplex Assay)], mitochondrial membrane potential (MMP; MitoProbe™ JC-1 Assay), mitochondrial network analysis (MitoTracker
Identifiants
pubmed: 36242655
doi: 10.1007/s00702-022-02548-8
pii: 10.1007/s00702-022-02548-8
doi:
Substances chimiques
Reactive Oxygen Species
0
Hydrogen Peroxide
BBX060AN9V
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1435-1446Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
Références
Bardien S, Keyser R, Yako Y et al (2009) Molecular analysis of the parkin gene in South African patients diagnosed with Parkinson’s disease. Park Relat Disord 15:116–121. https://doi.org/10.1016/j.parkreldis.2008.04.005
doi: 10.1016/j.parkreldis.2008.04.005
Bardien S, Marsberg A, Keyser R et al (2010) LRRK2 G2019S mutation: Frequency and haplotype data in South African Parkinson’s disease patients. J Neural Transm 117:847–853. https://doi.org/10.1007/s00702-010-0423-6
doi: 10.1007/s00702-010-0423-6
pubmed: 20544233
Belluzzi E, Greggio E, Piccoli G (2012) Presynaptic dysfunction in Parkinson’s disease: a focus on LRRK2. Biochem Soc Trans 40:1111–1116. https://doi.org/10.1042/bst20120124
doi: 10.1042/bst20120124
pubmed: 22988874
Blanckenberg J, Bardien S, Glanzmann B et al (2013) The prevalence and genetics of Parkinson’s disease in sub-Saharan Africans. J Neurol Sci 335:22–25. https://doi.org/10.1016/j.jns.2013.09.010
doi: 10.1016/j.jns.2013.09.010
pubmed: 24079843
Blanckenberg J, Ntsapi C, Carr JA, Bardien S (2014) EIF4G1 R1205H and VPS35 D620N mutations are rare in Parkinson’s disease from South Africa. Neurobiol Aging 35:445.e1-445.e3. https://doi.org/10.1016/j.neurobiolaging.2013.08.023
doi: 10.1016/j.neurobiolaging.2013.08.023
Blauwendraat C, Heilbron K, Vallerga CL et al (2019) Parkinson’s disease age at onset genome-wide association study: Defining heritability, genetic loci, and α-synuclein mechanisms. Mov Disord 34:866–875. https://doi.org/10.1002/mds.27659
doi: 10.1002/mds.27659
pubmed: 30957308
pmcid: 6579628
Bosco DA, Fowler DM, Zhang Q et al (2006) Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate α-synuclein fibrilization. Nat Chem Biol 2:249–253. https://doi.org/10.1038/nchembio782
doi: 10.1038/nchembio782
pubmed: 16565714
Chung SY, Kishinevsky S, Mazzulli JR et al (2016) Parkin and PINK1 patient iPSC-derived midbrain dopamine neurons exhibit mitochondrial dysfunction and α-synuclein accumulation. Stem Cell Reports 7:664–677. https://doi.org/10.1016/j.stemcr.2016.08.012
doi: 10.1016/j.stemcr.2016.08.012
pubmed: 27641647
pmcid: 5063469
Cilia R, Sironi F, Akpalu A et al (2012) Screening LRRK2 gene mutations in patients with Parkinson’s disease in Ghana. J Neurol 259:569–570. https://doi.org/10.1007/s00415-011-6210-y
doi: 10.1007/s00415-011-6210-y
pubmed: 21842440
Cotter TG, Al-Rubeai M (1995) Cell death (apoptosis) in cell culture systems. Trends Biotechnol 13:150–155. https://doi.org/10.1016/S0167-7799(00)88926-X
doi: 10.1016/S0167-7799(00)88926-X
pubmed: 7766111
Craig AM, Kang Y (2007) Neurexin-neuroligin signaling in synapse development. Curr Opin Neurobiol 17:43–52. https://doi.org/10.1016/j.conb.2007.01.011
doi: 10.1016/j.conb.2007.01.011
pubmed: 17275284
pmcid: 2820508
Cuttler K, Hassan M, Carr J et al (2021) Emerging evidence implicating a role for neurexins in neurodegenerative and neuropsychiatric disorders. Open Biol. https://doi.org/10.1098/RSOB.210091
doi: 10.1098/RSOB.210091
pubmed: 34610269
pmcid: 8492176
Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39:889–909. https://doi.org/10.1016/S0896-6273(03)00568-3
doi: 10.1016/S0896-6273(03)00568-3
pubmed: 12971891
de Rijk MC, Launer LJ, Berger K et al (2000) Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54:S21–S23
doi: 10.1212/WNL.54.5.21A
pubmed: 10854357
Feigin VL, Krishnamurthi RV, Theadom AM et al (2017) Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 16:877–897. https://doi.org/10.1016/S1474-4422(17)30299-5
doi: 10.1016/S1474-4422(17)30299-5
Floor E, Wetzel MG (1998) Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 70:268–275. https://doi.org/10.1046/j.1471-4159.1998.70010268.x
doi: 10.1046/j.1471-4159.1998.70010268.x
pubmed: 9422371
Fu LM, Fu KA (2015) Analysis of Parkinson’s disease pathophysiology using an integrated genomics-bioinformatics approach. Pathophysiology 22:15–29. https://doi.org/10.1016/j.pathophys.2014.10.002
doi: 10.1016/j.pathophys.2014.10.002
pubmed: 25466606
Goetzl EJ, Abner EL, Jicha GA et al (2018) Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer’s disease. FASEB J 32:888–893. https://doi.org/10.1096/fj.201700731R
doi: 10.1096/fj.201700731R
pubmed: 29025866
Gotow T, Miyaguchi K, Hashimoto PH (1991) Cytoplasmic architecture of the axon terminal: filamentous strands specifically associated with synaptic vesicles. Neuroscience 40:587–598. https://doi.org/10.1016/0306-4522(91)90143-C
doi: 10.1016/0306-4522(91)90143-C
pubmed: 2027472
Huang P, Galloway CA, Yoon Y (2011) Control of mitochondrial morphology through differential interactions of mitochondrial fusion and fission proteins. PLoS ONE 6:e20655. https://doi.org/10.1371/journal.pone.0020655
doi: 10.1371/journal.pone.0020655
pubmed: 21647385
pmcid: 3103587
Jankovic J (2008) Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79:368–375. https://doi.org/10.1136/jnnp.2007.131045
doi: 10.1136/jnnp.2007.131045
pubmed: 18344392
Kang Y, Zhang X, Dobie F et al (2008) Induction of GABAergic postsynaptic differentiation by α-neurexins. J Biol Chem 283:2323–2334. https://doi.org/10.1074/jbc.M703957200
doi: 10.1074/jbc.M703957200
pubmed: 18006501
Kattimani Y, Veerappa AM (2018) Dysregulation of NRXN1 by mutant MIR8485 leads to calcium overload in pre-synapses inducing neurodegeneration in Multiple sclerosis. Mult Scler Relat Disord 22:153–156. https://doi.org/10.1016/j.msard.2018.04.005
doi: 10.1016/j.msard.2018.04.005
pubmed: 29729524
Keyser RJ, van der Merwe L, Venter M et al (2009) Identification of a novel functional deletion variant in the 5’-UTR of the DJ-1 gene. BMC Med Genet 10:105. https://doi.org/10.1186/1471-2350-10-105
doi: 10.1186/1471-2350-10-105
pubmed: 19825160
pmcid: 2767350
Keyser RJ, Lesage S, Brice A et al (2010) Assessing the prevalence of PINK1 genetic variants in South African patients diagnosed with early- and late-onset Parkinson’s disease. Biochem Biophys Res Commun 398:125–129. https://doi.org/10.1016/j.bbrc.2010.06.049
doi: 10.1016/j.bbrc.2010.06.049
pubmed: 20558144
Klein C, Westenberger A (2012) Genetics of Parkinson’s disease. Cold Spring Harb Perspect Med. https://doi.org/10.1101/cshperspect.a008888
doi: 10.1101/cshperspect.a008888
pubmed: 22315721
pmcid: 3253033
Krueger DD, Tuffy LP, Papadopoulos T, Brose N (2012) The role of neurexins and neuroligins in the formation, maturation, and function of vertebrate synapses. Curr Opin Neurobiol 22:412–422. https://doi.org/10.1016/j.conb.2012.02.012
doi: 10.1016/j.conb.2012.02.012
pubmed: 22424845
Lepeta K, Lourenco MV, Schweitzer BC et al (2016) Synaptopathies: synaptic dysfunction in neurological disorders: a review from students to students. J Neurochem 138:785–805. https://doi.org/10.1111/jnc.13713
doi: 10.1111/jnc.13713
pubmed: 27333343
pmcid: 5095804
Lill CM (2016) Genetics of Parkinson’s disease. Mol Cell Probes 3:386–396. https://doi.org/10.1016/j.mcp.2016.11.001
doi: 10.1016/j.mcp.2016.11.001
Lima MMS, Reksidler ABB, Vital MABF (2009) The neurobiology of the substantia nigra pars compacta: From motor to sleep regulation. In: Giovanni G, Di Matteo V, Esposito E (eds) Journal of Neural Transmission Supplementa: Birth, Life and Death of Dopaminergic Neurons in the Substantia Nigra. Springer, Vienna, pp 135–145
doi: 10.1007/978-3-211-92660-4_11
Lleó A, Núñez-Llaves R, Alcolea D et al (2019) Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer’s disease cerebrospinal fluid. Mol Cell Proteom 18:546–560. https://doi.org/10.1074/mcp.RA118.001290
doi: 10.1074/mcp.RA118.001290
MacDonald AA, Seergobin KN, Owen AM et al (2013) Differential effects of Parkinson’s disease and dopamine replacement on memory encoding and retrieval. PLoS ONE. https://doi.org/10.1371/journal.pone.0074044
doi: 10.1371/journal.pone.0074044
pubmed: 24416096
pmcid: 3877271
Mattson MP, Liu D (2002) Energetics and oxidative stress in synaptic plasticity and neurodegenerative disorders. Neuro Mol Med 2:215–232. https://doi.org/10.1385/NMM:2:2:215
doi: 10.1385/NMM:2:2:215
Merrill RA, Flippo KH, Strack S (2017) Measuring mitochondrial shape with imageJ. Neuromethods. Humana Press Inc, London, pp 31–48
Missler M, Südhof TC (1998) Neurexins: three genes and 1001 products. Trends Genet 14:20–26. https://doi.org/10.1016/S0168-9525(97)01324-3
doi: 10.1016/S0168-9525(97)01324-3
pubmed: 9448462
Morris RL, Hollenbeck PJ (1993) The regulation of bidirectional mitochondrial transport is coordinated with axonal outgrowth. J Cell Sci 104:917–927. https://doi.org/10.1242/jcs.104.3.917
doi: 10.1242/jcs.104.3.917
pubmed: 8314882
Nakabeppu Y, Tsuchimoto D, Yamaguchi H, Sakumi K (2007) Oxidative damage in nucleic acids and Parkinson’s disease. J Neurosci Res 85:919–934. https://doi.org/10.1002/jnr.21191
doi: 10.1002/jnr.21191
pubmed: 17279544
Nguyen HN, Byers B, Cord B et al (2011) LRRK2 mutant iPSC-derived da neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 8:267–280. https://doi.org/10.1016/j.stem.2011.01.013
doi: 10.1016/j.stem.2011.01.013
pubmed: 21362567
pmcid: 3578553
Nguyen M, Wong YC, Ysselstein D et al (2019) Synaptic, mitochondrial, and lysosomal dysfunction in Parkinson’s disease. Trends Neurosci 42:140–149. https://doi.org/10.1016/j.tins.2018.11.001
doi: 10.1016/j.tins.2018.11.001
pubmed: 30509690
Okubadejo N, Britton A, Crews C et al (2008) Analysis of Nigerians with apparently sporadic Parkinson disease for mutations in LRRK2, PRKN and ATXN3. PLoS ONE. https://doi.org/10.1371/journal.pone.0003421
doi: 10.1371/journal.pone.0003421
pubmed: 18927607
pmcid: 2559870
Picconi B, Piccoli G, Calabresi P (2012) Synaptic dysfunction in Parkinson’s disease. In: Kreutz M, Sala C (eds) Advances in experimental medicine and biology: synaptic plasticity. Springe, Vienna, pp 553–572
doi: 10.1007/978-3-7091-0932-8_24
Plum S, Eggers B, Helling S et al (2020) Proteomic characterization of synaptosomes from human substantia Nigra indicates altered mitochondrial translation in Parkinson’s disease. Cells 9:2580. https://doi.org/10.3390/cells9122580
doi: 10.3390/cells9122580
pmcid: 7761546
Puschmann A (2017) New genes causing hereditary Parkinson’s disease or Parkinsonism. Curr Neurol Neurosci Rep 17:66. https://doi.org/10.1007/s11910-017-0780-8
doi: 10.1007/s11910-017-0780-8
pubmed: 28733970
pmcid: 5522513
Rego AC, Oliveira CR (2003) Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases. Neurochem Res 28:1563–1574. https://doi.org/10.1023/A:1025682611389
doi: 10.1023/A:1025682611389
pubmed: 14570402
Ruthel G, Hollenbeck PJ (2003) Response of mitochondrial traffic to axon determination and differential branch growth. J Neurosci 23:8618–8624. https://doi.org/10.1523/JNEUROSCI.23-24-08618.2003
doi: 10.1523/JNEUROSCI.23-24-08618.2003
pubmed: 13679431
pmcid: 6740379
Sebate B, Cuttler K, Cloete R et al (2021) Prioritization of candidate genes for a South African family with Parkinson’s disease using in-silico tools. PLoS ONE 16:e0249324. https://doi.org/10.1371/journal.pone.0249324
doi: 10.1371/journal.pone.0249324
pubmed: 33770142
pmcid: 7997022
Shi Y (2002) Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 9:459–470. https://doi.org/10.1016/S1097-2765(02)00482-3
doi: 10.1016/S1097-2765(02)00482-3
pubmed: 11931755
Sunkin SM, Ng L, Lau C et al (2012) Allen Brain Atlas: An integrated spatio-temporal portal for exploring the central nervous system. Nucleic Acids Res 41:D996–D1008. https://doi.org/10.1093/nar/gks1042
doi: 10.1093/nar/gks1042
pubmed: 23193282
pmcid: 3531093
Surmeier DJ, Obeso JA, Halliday GM (2017) Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci 18:101–113. https://doi.org/10.1038/nrn.2016.178
doi: 10.1038/nrn.2016.178
pubmed: 28104909
pmcid: 5564322
Taoufik E, Kouroupi G, Zygogianni O, Matsas R (2018) Synaptic dysfunction in neurodegenerative and neurodevelopmental diseases: an overview of induced pluripotent stem-cell-based disease models. Open Biol. https://doi.org/10.1098/rsob.180138
doi: 10.1098/rsob.180138
pubmed: 30185603
pmcid: 6170506
Treeck H-H, Pirsig W (1979) Differentiation of nerve endings in the cochlear nucleus on morphological and experimental basis. Acta Otolaryngol 87:47–60. https://doi.org/10.3109/00016487909126386
doi: 10.3109/00016487909126386
pubmed: 760377
Tyson T, Steiner JA, Brundin P (2016) Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology. J Neurochem 139:275–289. https://doi.org/10.1111/jnc.13449
doi: 10.1111/jnc.13449
pubmed: 26617280
pmcid: 4958606
van der Merwe C, Carr J, Glanzmann B, Bardien S (2016) Exonic rearrangements in the known Parkinson’s disease-causing genes are a rare cause of the disease in South African patients. Neurosci Lett 619:168–171. https://doi.org/10.1016/j.neulet.2016.03.028
doi: 10.1016/j.neulet.2016.03.028
pubmed: 27001088
Wang T, Larcher LM, Ma L, Veedu RN (2018) Systematic screening of commonly used commercial transfection reagents towards efficient transfection of single-stranded oligonucleotides. Molecules. https://doi.org/10.3390/molecules23102564
doi: 10.3390/molecules23102564
pubmed: 30602709
pmcid: 6337709
Winklhofer KF, Haass C (2010) Mitochondrial dysfunction in Parkinson’s disease. Biochim Biophys Acta Mol Basis Dis 1802:29–44. https://doi.org/10.1016/j.bbadis.2009.08.013
doi: 10.1016/j.bbadis.2009.08.013
Yasuda T, Mochizuki H (2010) The regulatory role of α-synuclein and parkin in neuronal cell apoptosis; Possible implications for the pathogenesis of Parkinson’s disease. Apoptosis 15:1312–1321. https://doi.org/10.1007/s10495-010-0486-8
doi: 10.1007/s10495-010-0486-8
pubmed: 20221696
Yonova-Doing E, Atadzhanov M, Quadri M et al (2012) Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson’s disease. Park Relat Disord 18:567–571. https://doi.org/10.1016/j.parkreldis.2012.02.018
doi: 10.1016/j.parkreldis.2012.02.018
Zorova LD, Popkov VA, Plotnikov EY et al (2018) Mitochondrial membrane potential. Anal Biochem 552:50–59. https://doi.org/10.1016/j.ab.2017.07.009
doi: 10.1016/j.ab.2017.07.009
pubmed: 28711444